Adaptive Biotechnologies
Business Services · Washington, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
1165 Eastlake Ave E, Seattle, Washington...Phone Number
(206) 659-0067Website
www.adaptivebiotech.comRevenue
$295.4 MillionStock Symbol
ADPTIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
4
1
2
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detRead more
Adaptive Biotechnologies Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Adaptive Biotechnologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Adaptive Biotechnologies has new funding data
Adaptive Biotechnologies, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Adaptive Biotechnologies
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Adaptive Biotechnologies recently announced quarterly report
Check out if Adaptive Biotechnologies is spiking on competitors!
Product Launch: Get notified when Adaptive Biotechnologies launches new products
Check if Adaptive Biotechnologies has recently received funding, and reach out quickly before it becomes old news!
Click to see if Adaptive Biotechnologies had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Adaptive Biotechnologies
Find 3 more new buyers
Compare Similar Companies to Adaptive Biotechnologies
Compare insights from companies similar to Adaptive Biotechnologies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Adaptive Biotechnologies
$295.4M
501-1,000
Public
$1B
2009
CR
Chad RobinsCEO, Co-Founder & Chairman of the Board
Company Profile Activity
Activity Insights
Adaptive Biotechnologies is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Adaptive Biotechnologies is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Adaptive Biotechnologies.
Adaptive Biotechnologies financials insights
Gather financial insights about Adaptive Biotechnologies, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Series A
$5.8M
2012
Series B
$2.6M
2014
Series C
$5M
Series D
$100M
2015
Series E
$94M
Series F
$195M
2017
Corporate Investment
$45M
2019
Stock Offering
$345M
2022
Other Financing Round
$250M
Adaptive Biotechnologies Tech Stack
A closer look at the technologies used by Adaptive Biotechnologies
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Person-Based
Earnings, Finance
Person-Based
Adaptive Biotechnologies News & Media
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
Over 30 presentations at ASCO and EHA leverage clonoSEQ MRD testing to assess novel therapies and support MRD-guided patient care across blood cancersHarvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million
Adaptive Biotechnologies develops immune-driven diagnostics and research tools for the life sciences and healthcare sectors.Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
SEATTLE, May 21, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences.Adaptive Biotechnologies Q1 Earnings Call Highlights
Adaptive Biotechnologies (NASDAQ:ADPT) reported first-quarter 2026 results that executives said showed “accelerating momentum” in measurable residual disease (MRD) testing, alongside continued operational efficiency gains and a higher full-year MRD revenue outlook. MRD growth drives revenue as comp
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Adaptive Biotechnologies
Sign Up For FreeTo access detailed company insights
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adapt... Read More
